[go: up one dir, main page]

MX2024005663A - Composicion farmaceutica de agonista dual del receptor glp-1 y del receptor gip, y uso del mismo. - Google Patents

Composicion farmaceutica de agonista dual del receptor glp-1 y del receptor gip, y uso del mismo.

Info

Publication number
MX2024005663A
MX2024005663A MX2024005663A MX2024005663A MX2024005663A MX 2024005663 A MX2024005663 A MX 2024005663A MX 2024005663 A MX2024005663 A MX 2024005663A MX 2024005663 A MX2024005663 A MX 2024005663A MX 2024005663 A MX2024005663 A MX 2024005663A
Authority
MX
Mexico
Prior art keywords
sub
receptor
pharmaceutical composition
ser
glp
Prior art date
Application number
MX2024005663A
Other languages
English (en)
Inventor
Jing Chen
Kai Liu
Zhenbin Li
Xueteng Cao
Original Assignee
Fujian Shengdi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujian Shengdi Pharmaceutical Co Ltd filed Critical Fujian Shengdi Pharmaceutical Co Ltd
Publication of MX2024005663A publication Critical patent/MX2024005663A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención refiere a una composición farmacéutica de un agonista dual del receptor GLP-1 y del receptor GIP, y uso del mismo. Específicamente, la composición farmacéutica comprende un análogo de GLP-1 como se muestra en la fórmula general (I), y un amortiguador como un amortiguador de fosfato; la composición también puede incluir un osmoregulador como propilenglicol, cloruro de sodio o manitol. La composición farmacéutica tiene buena actividad biológica y estabilidad. La fórmula general (I) es: R1-X1-X2-Glu-Gly-Thr-Phe-Thr-Ser-Asp-X10-Ser-X12-X13-X14-X15-X 16-X17-X18-X19-X20-Glu-Phe-X23-X24-Trp-Leu-X27-X28-X29-X30-Pro-Se r-Ser-Gly-Ala Pro-Pro-Pro-Ser-R2.
MX2024005663A 2021-11-12 2022-11-11 Composicion farmaceutica de agonista dual del receptor glp-1 y del receptor gip, y uso del mismo. MX2024005663A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202111341752 2021-11-12
PCT/CN2022/131375 WO2023083301A1 (zh) 2021-11-12 2022-11-11 Glp-1受体和gip受体双重激动剂的药物组合物及其用途

Publications (1)

Publication Number Publication Date
MX2024005663A true MX2024005663A (es) 2024-05-28

Family

ID=86335124

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024005663A MX2024005663A (es) 2021-11-12 2022-11-11 Composicion farmaceutica de agonista dual del receptor glp-1 y del receptor gip, y uso del mismo.

Country Status (10)

Country Link
US (1) US20250115654A1 (es)
EP (1) EP4431522A4 (es)
JP (1) JP2024546026A (es)
KR (1) KR20240109258A (es)
CN (1) CN118103391A (es)
AU (1) AU2022386489A1 (es)
CA (1) CA3237796A1 (es)
MX (1) MX2024005663A (es)
TW (1) TW202333773A (es)
WO (1) WO2023083301A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116693652B (zh) * 2023-08-02 2024-01-05 北京惠之衡生物科技有限公司 一种glp-1/gip受体双重激动剂衍生物及其制备方法和应用
WO2025124473A1 (zh) * 2023-12-12 2025-06-19 江苏恒瑞医药股份有限公司 Glp-1类似物治疗代谢疾病的方法及医药用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101987868B (zh) * 2009-07-30 2013-09-04 江苏豪森医药集团有限公司 Glp-1类似物的衍生物或其可药用盐和用途
WO2012088379A2 (en) * 2010-12-22 2012-06-28 Marcadia Biotech, Inc. Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
WO2012167744A1 (en) * 2011-06-10 2012-12-13 Beijing Hanmi Pharmaceutical Co., Ltd. Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
CA2872314C (en) * 2012-05-03 2021-08-31 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
HK1211231A1 (en) * 2012-12-21 2016-05-20 Sanofi Exendin-4 derivatives
JP7250706B2 (ja) * 2017-06-21 2023-04-03 アムジエン・インコーポレーテツド 胃抑制ペプチド受容体（ｇｉｐｒ）に対するアンタゴニスト結合タンパク質／ｇｌｐ－１受容体アゴニスト融合タンパク質を使用した代謝障害の治療又は寛解方法
RS64438B1 (sr) * 2018-10-26 2023-09-29 Novo Nordisk As Stabilne kompozicije semaglutida i njihova upotreba
EP3954701A4 (en) * 2019-04-11 2023-09-06 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. MULTIRECEPTOR AGONIST AND MEDICAL USE THEREOF
US20220372072A1 (en) * 2019-09-19 2022-11-24 Dr. Reddy's Laboratories Limited Improved purification processes for liraglutide
KR20220119731A (ko) * 2019-12-30 2022-08-30 간 앤 리 파마슈티칼스 컴퍼니, 리미티드 장기 지속형 glp-1 화합물
CN118530333A (zh) * 2020-05-29 2024-08-23 北京拓界生物医药科技有限公司 Glp-1和gip受体双重激动剂化合物及其应用

Also Published As

Publication number Publication date
WO2023083301A1 (zh) 2023-05-19
US20250115654A1 (en) 2025-04-10
CA3237796A1 (en) 2023-05-19
TW202333773A (zh) 2023-09-01
CN118103391A (zh) 2024-05-28
EP4431522A4 (en) 2025-03-26
JP2024546026A (ja) 2024-12-17
AU2022386489A1 (en) 2024-05-23
KR20240109258A (ko) 2024-07-10
EP4431522A1 (en) 2024-09-18

Similar Documents

Publication Publication Date Title
MX2024005663A (es) Composicion farmaceutica de agonista dual del receptor glp-1 y del receptor gip, y uso del mismo.
CR20230066A (es) Agonistas del glp-1 heterocíclicos
NO2021008I1 (no) fedratinib eller et farmasøytisk akseptabelt salt derav
EA200200360A1 (ru) Производные пурина
EA200201179A1 (ru) Производные 2-аминокарбонил-9h-пурина
BRPI0417684A (pt) composto, composição farmacêutica, e, uso de um composto
PE20001225A1 (es) Derivados de adenina
DK0939627T3 (da) Pentaflourbenzensulfonamider og analoger
BR0015605A (pt) Composição e uso
PA8548701A1 (es) Azaindoles
BR0213562A (pt) Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna
GT200300294A (es) Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas y procedimientos para su uso
BR112022010891A2 (pt) Combinação de um antagonista do receptor lpa1 de azetidina com agentes antifibróticos
PA8495101A1 (es) Derivados de 13-metileritromicina
NZ780977A (en) Pharmaceutical parenteral composition of dual glp1/2 agonist
BR112023019435A2 (pt) Inibidores de nek7
DOP2024000172A (es) Compuestos antivirales y métodos de elaboración y uso de los mismos
CO2024015820A2 (es) Compuestos de heteroarilo para el tratamiento del dolor
MX2022006453A (es) Compuesto que contiene anillo de benceno y aplicacion del mismo.
DOP2022000073A (es) Derivados de 2-azaspiro[3,4]octano como agonistas de m4
BR112023016986A2 (pt) Compostos de aminopirimidina e métodos de seu uso
MX2021000403A (es) Composicion de derivados de aminoacido gamma triciclico fusionados y la preparacion de la misma.
ES2113533T3 (es) Composiciones farmaceuticas de alquilsulfonamidas agonistas de 5-ht1 para administracion rectal.
DOP2024000171A (es) Compuestos antivirales y métodos de elaboración y uso de los mismos
UY38907A (es) Compuestos derivados de 2–azaespiro[3.4]octano como agonistas de m4 y composiciones de los mismos